The Skye team has wrapped up two busy weeks of conferences. You can find webcasts below: Guggenheim Healthcare Conference (fireside chat): https://bit.ly/3ACtgbG UBS Healthcare Conference (fireside chat): https://bit.ly/490R4Cv Stifel Healthcare Conference (presentation): https://bit.ly/4i0lbyj
Skye Bioscience Inc.
生物技术研究
San Diego，CA 2,162 位关注者
Unlocking new therapeutic pathways for metabolic health
关于我们
Skye Bioscience (Nasdaq: SKYE) is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye plans to start a Phase 2 clinical trial in obesity in Q3 2024 for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1, comparing monotherapy and combination arms of nimacimab and a GLP-1R agonist (Wegovy?).
- 网站
-
https://www.skyebioscience.com
Skye Bioscience Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- San Diego，CA
- 类型
- 上市公司
- 创立
- 2011
地点
-
主要
获取路线
12250 El Camino Real Drive
Suite 100
US，CA，San Diego，92130
Skye Bioscience Inc.员工
动态
-
Skye looks forward to rounding out a busy conference year by participating in these upcoming healthcare investment conferences. All webcasts will be accessible on our website. Read the full article here: https://bit.ly/4hR0Uer
-
-
Skye expects to report interim data for the CBeyond??Phase 2 clinical trial in Q2 2025 after this initial set of enrolled patients has completed the 26-week treatment period. Read the full article here: https://bit.ly/3URs0bx
-
-
Skye hosted a satellite presentation on Nov. 5th during ObesityWeek 2024. Discover how Skye's drug, nimacimab, stands out by achieving effective peripheral CB1 inhibition without central exposure (and its risk of neuropsychiatric adverse events), leading to powerful benefits: dose-dependent weight loss, fat mass reduction with lean mass preservation, and improved glycemic control. Watch our full presentation here: https://lnkd.in/gxx2PbdP
-
-
Preliminary data from Skye's newly-developed diet-induced obesity (DIO) model in mice fulfilled its initial objective of showing that peripheral CB1 inhibition achieves significant weight loss without relying on central activity and its risk of neuropsychiatric adverse events. Skye’s peripherally-targeting antibody, nimacimab, a CB1 inverse agonist and antagonist, achieved dose-dependent weight loss of up to 16% compared to vehicle. Read the full article here: https://bit.ly/4fQ49B9
-
-
We are looking forward to participating in upcoming healthcare conferences. Available webcasts will be accessible on our website. Click here to read the full article: https://bit.ly/3YAsgwH
-
-
“It is clear that with increased restriction from the brain, nimacimab provides a potential safety advantage over a small molecule approach..." Skye CEO, Punit Dhillon said. Read the full article here: https://bit.ly/47EeaOX
-
-
We are looking forward to our formal presentation and investor meetings at #CantorHCC where Punit and Puneet will be representing Skye. View the webcast live on Sept 19 at 8:35am ET or the archive: https://lnkd.in/gRxa-jea
-
-
Skye looks forward to its fireside chat and meetings at Morgan Stanley on Friday, September 6th at 1:50 pm ET. Join the Webcast here, or watch the archived version: https://lnkd.in/gkFax6_C #MSHealthcare
-
-
Skye welcomes Puneet S. Arora, MD, MS, FACE, in the newly created role of Chief Medical Officer (CMO). Dr. Arora was previously at Lassen Therapeutics, Principia Biopharma, a Sanofi company, and Genentech. He is an endocrinologist with extensive experience in metabolic diseases, including obesity. Read the full article here: https://bit.ly/47es2PA
-